Related Experiment Videos
Effector functions and control of human gammadelta T-cell activation
1Paul-Ehrlich-Institute, Dept. of Immunology, Langen, Germany.
Microbes and Infection
|May 9, 2000
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Stochastics of Cellular Differentiation Explained by Epigenetics: The Case of T-Cell Differentiation and Functional Plasticity.
Scandinavian journal of immunology·2017
CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Scandinavian journal of immunology·2017
[Effector memory T‑cells in the pathogenesis of ANCA-associated vasculitides. German version].
Zeitschrift fur Rheumatologie·2016
Effector memory T‑cells in the pathogenesis of ANCA-associated vasculitides.
Zeitschrift fur Rheumatologie·2016
Lysosome-Related Effector Vesicles in T Lymphocytes and NK Cells.
Scandinavian journal of immunology·2015
Inhibition of human γδ T cell proliferation and effector functions by neutrophil serine proteases.
Scandinavian journal of immunology·2014
Laboratory parameters and serum tube agglutination test as markers for brucellosis treatment response.
Microbes and infection·2025
ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?
Annals of surgical oncology·2026
[Analysis of clinicopathological and immunological characteristics of patients with acquired immune deficiency syndrome-associated diffuse large B-cell lymphoma complicated by Talaromyces marneffei infection].
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026
Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026